Oncology Biomarkers

The identification of cancer through the microscopic examination of stained tissue sections from tumors remains the established gold standard for diagnosis. However, to enhance patient treatment optimization and offer guidance for therapeutic interventions, there arises a frequent necessity for additional methods to stratify tumors effectively.

Analyzing protein expression within tumor tissues provides valuable supplementary information to pathologists. Immunohistochemistry (IHC), utilizing protein-specific antibodies, becomes a pivotal tool for detecting the presence, abundance, and localization of specific proteins. Given the currently limited repertoire of available protein biomarkers, there exists a clear and unmet clinical demand to uncover novel sets of biomarkers. The overarching objective is to deliver a more precise diagnosis and a more thorough assessment of patient prognosis, ultimately paving the way for more individualized treatment plans.

Atlas Antibodies not only acknowledges but actively addresses the need for new biomarkers. In collaboration with our research partners in the Human Protein Atlas project, we are uniquely positioned to engage in antibody-based biomarker discovery. This collaborative effort aims to contribute significantly to advancing diagnostic accuracy, refining prognostic evaluations, and ultimately fostering a new era of more personalised and effective cancer treatments.

DOWNLOAD WHITE PAPER